Publikationen (54) Publikationen, an denen Forscher/innen teilgenommen haben

2024

  1. Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/RUNX1::RUNX1T1: Selecting Optimal Treatment Based on Clinical and Molecular Findings

    Biomedicines, Vol. 12, Núm. 10

  2. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  3. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

    eClinicalMedicine, Vol. 73

  4. Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients

    Blood cancer journal

  5. Killer-cell immunoglobulin-like receptor polymorphism is associated with COVID-19 outcome: Results of a pilot observational study

    HLA, Vol. 104, Núm. 2

  6. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease

    British Journal of Haematology, Vol. 205, Núm. 1, pp. 109-121

  7. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  8. Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient

    Biomedicines, Vol. 12, Núm. 1

  9. Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia

    Biomarker Research

2023

  1. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    Blood Cancer Journal

  2. Characterization of Three Somatic Mutations in the 3′UTR of RRAS2 and Their Inverse Correlation with Lymphocytosis in Chronic Lymphocytic Leukemia

    Cells, Vol. 12, Núm. 23

  3. Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level

    Disease models & mechanisms, Vol. 16, Núm. 8

  4. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

    Blood, Vol. 141, Núm. 2, pp. 156-167

  5. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  6. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  7. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study

    Cancers, Vol. 15, Núm. 5

  8. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

  9. Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution

    Cancers, Vol. 15, Núm. 3

  10. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

    Blood Advances, Vol. 6, Núm. 21, pp. 5763-5773